Bain Capital Life Sciences

Andrew Hack is a Partner on the Life Sciences team at Bain Capital, which he joined in 2019. He previously served as Chief Financial Officer of Editas Medicine and as a portfolio manager at Millennium Management running a market-neutral healthcare hedge fund, and earlier worked as a securities analyst at healthcare-focused hedge funds and banks and as Director of Life Sciences at Reify Corporation. He holds an MD and PhD in molecular genetics and cell biology and an AB in biology, all from the University of Chicago.

Nicholas Downing is a Partner on the Life Sciences team at Bain Capital, which he joined in 2018. He previously was a resident physician at Brigham and Women's Hospital in Boston and worked as a consultant at McKinsey & Company, serving pharmaceutical, hospital, and financial services clients. He has authored more than 40 peer-reviewed articles and holds a chemistry degree from Harvard College and an MD from Yale University School of Medicine.

Ricky Sun is a Partner on Bain Capital's Life Sciences team, which he joined in 2016. Before Bain Capital, he was Director of Corporate Development and Strategy at Biogen, a Vice President at BlackRock, and a healthcare analyst at Citadel, Alyeska Investment Group, Lehman Brothers, and Morgan Stanley; he began his career as a senior scientist at Ironwood Pharmaceuticals. He holds a PhD in chemistry and chemical biology from Harvard, an MBA from NYU Stern, and a BA in chemistry from Berea College.

Darren Abrahamson is a Partner on Bain Capital's Tech Opportunities team, having joined the firm in 2005. He leads investments across application software, infrastructure, cybersecurity, financial technology, and healthcare IT, and previously led the Technology vertical within the North America Private Equity team. He holds an MBA from Harvard Business School and a BS in economics from the Wharton School at the University of Pennsylvania.

Managing Director in Bain Capital's Private Equity business, based in London.

Partner in Bain Capital's Private Equity business, based in London.

Partner in Bain Capital's Private Equity business.

Adam M. Koppel is a Partner on the Life Sciences team at Bain Capital, which he first joined in 2003 and rejoined in 2016, having earlier been part of the firm's Public Equity team focused on healthcare. Between his stints at Bain Capital, he served as EVP of Corporate Development and Chief Strategy Officer at Biogen, and prior to that was an Associate Principal at McKinsey & Company. He holds an MD and PhD in neuroscience and an MBA from the University of Pennsylvania, and an AB and AM in history and science from Harvard University.

Evan Greif is a Principal on the Life Sciences team at Bain Capital, which he joined in 2020. Before that, he worked as an Analyst covering healthcare at Orbis Investments and as an Associate Consultant at Bain & Company. He holds a BA in applied mathematics and an MA in statistics from Harvard University, along with a MAST in pure mathematics from Cambridge University.

John Trzupek joined Bain Capital in 2025 as a Managing Director on the Life Sciences team. He previously served as COO and CFO at Abata Therapeutics and Chief Business Officer at KSQ Therapeutics, and held business and scientific roles at Pfizer, including Director of Strategy for inflammation and immunology. He began his career as a Research Fellow at Memorial Sloan-Kettering Cancer Center.

Lei Meng is a Managing Director on the Life Sciences team at Bain Capital, which she joined in 2024. She previously worked in therapeutics private investments at Avidity Partners and held roles in marketing analytics and business development at Allergan, as well as earlier positions at Merck & Co, Forest Labs, McKinsey & Company, and Samlyn Capital. She holds an MA in chemistry from Harvard University, an MBA from INSEAD, and a BA in biochemistry from Barnard College, Columbia University.

Leonard Feiner, MD, PhD, is a Principal on the Life Sciences team at Bain Capital, which he joined in 2021. Before that, he worked as a vitreoretinal surgeon and served as principal investigator on over 50 clinical trials covering conditions such as macular degeneration, diabetic macular edema, and retinal vein occlusion. He holds a degree in mechanical and aerospace engineering from Princeton University and an MD/PhD from the University of Pennsylvania, with an ophthalmology residency at Penn and a surgical retina fellowship at Washington University in St. Louis.

Matthew Calistri is a Managing Director in the Portfolio Group of Bain Capital's Life Sciences business, which he joined in 2024. He previously spent four years at Cerevel Therapeutics, serving as VP of Investor Relations and VP of Corporate Strategy, and held investor relations roles at Sage and Biogen. Earlier in his career he worked in financial services at Gerson Lehrman Group, ITG, UBS, Bankers Trust, and E&Y, and he holds an MBA in finance from the University of Chicago Booth School of Business and a BS in accounting from Fordham University.

Renjie Wang is a Managing Director on the Life Sciences team at Bain Capital, which she joined in 2014. She previously worked at Hony Capital, where she closed buyout, minority investment, and privatization transactions in the healthcare sector. She holds a master of finance from Peking University and a BA in economics from Fudan University.

Will Cozean is a Managing Director on Bain Capital's Life Sciences team, which he joined in 2013. He previously worked on the firm's North America Private Equity team in the Healthcare vertical, as well as its Industrial and Technology verticals, and earlier was a consultant at McKinsey & Company in Atlanta. He holds an MBA from Harvard Business School (Baker Scholar) and a BS in commerce from the University of Virginia (Jefferson Scholar).

Adam Fogel is a Director on the Credit team at Bain Capital, where he works in the Industry Research Group and joined in 2018. Before Bain Capital, he worked at Bayside Capital and Rothschild & Co. He holds a BA from the University of Pennsylvania.

Carlos Argilagos is a Director on the Public Equity team at Bain Capital, which he joined in 2010, where his work covers reporting, performance analysis, and risk management. He previously worked at FTI Consulting in Strategic Communications and at Liberty Mutual in Enterprise Risk Management. He holds a BS from MIT and an MBA from Boston University, and is a CFA charterholder and FRM designation holder.

Principal in Bain Capital's Insurance business, based in Boston.

Drew Field is a Principal on the Life Sciences team at Bain Capital, which he joined in 2020. Before that, he was a management consultant at Bain & Company in New York, working with healthcare and private equity clients, and previously held commercial strategy and investor relations roles at a biotech company. He holds a BA in biology and economics from Dartmouth College.

Jonah Cashdan is a Principal on the Life Sciences team at Bain Capital, which he joined in 2018. He previously worked in J.P. Morgan's healthcare investment banking group on M&A and financings for pharmaceutical, biotech, and medtech clients, and earlier studied synaptic physiology and sensory system development in labs at Georgetown University. He holds a BS in Neurobiology from Georgetown University.

Alyson Goff joined Bain Capital in 2025 as an Associate in the Portfolio Group for the Life Sciences business. Before that, she worked as a management consultant at Guidehouse in Boston, advising life-science sector clients on strategic initiatives. She holds an MS in biotechnology enterprise and entrepreneurship from Johns Hopkins University and a BA in biology from Boston University.

Amarilice Young joined Bain Capital in 2025 as Associate General Counsel for Life Sciences. She was previously a partner in the Life Sciences group at Goodwin Procter LLP. She holds a JD from University of Pennsylvania Law School and a BA in American Studies from Cornell University, and is a member of the Massachusetts and New York state bars.

Chiaka Ibe is an Associate on the Bain Capital Life Sciences team, which she joined in 2024. She was previously a management consultant at Bain & Company, advising clients in the Private Equity Group and Healthcare & Life Sciences practice, and worked as an analyst on the Health & Life Sciences team at Gates Ventures. She holds a BA in international health and human biology from Brown University.

Daniyal Sachee is an Associate on the Life Sciences team at Bain Capital, which he joined in 2025. He previously worked in the healthcare investment banking group at Goldman Sachs, advising on M&A, debt and equity financings, and royalty monetizations across the biotech and pharmaceutical sectors, and earlier conducted research on rare epilepsy-related disorders at Boston Children's Hospital. He holds a BA in Computational Neuroscience from Harvard.

Greg Koskinas is Chief Financial Officer for the Life Sciences business at Bain Capital, which he first joined in 2000 and rejoined in 2024. He was an original member of the firm's Absolute Return Capital business, overseeing trading and operational functions, and earlier worked in the finance group of the Public Equity business. Before returning to Bain Capital, he served as Chief Operating Officer and Chief Compliance Officer at ThornTree Capital Partners. He holds a BA in business and economics from Lafayette College.

Isaac Cheng is a Vice President on the Life Sciences team at Bain Capital, which he joined in 2024. He previously held business development and strategy roles in the pharmaceuticals unit at Johnson & Johnson, and evaluated business development and licensing opportunities across pharmaceuticals, MedTech, and services at AbbVie (via its acquisition of Allergan). He began his life sciences career as a management consultant at ZS Associates.

Jay Corrigan is a Partner and Group Chief Financial Officer for Private Markets at Bain Capital, which he joined in 1996. He oversees the finance teams across the firm's Private Equity, Venture, Crypto, Double Impact, Life Sciences, Tech Opportunities, and Real Estate businesses, and also serves as CFO for Double Impact. Before Bain Capital he worked for three years at Ernst & Young, and he holds a BS in accounting from Fordham University.

Jennie Daisak is a Vice President on the Life Sciences team at Bain Capital, which she joined in 2021. Before Bain Capital, she worked in J.P. Morgan's healthcare investment banking group, advising biotechnology and pharmaceutical clients on M&A and debt/equity financings. She graduated from the University of Pennsylvania's Vagelos Program in Life Sciences & Management, earning a BA in biology and a BS in economics from the Wharton School with a finance concentration.

Kristen Deftos is a Partner and Head of Human Resources at Bain Capital, where she has worked since 2012, overseeing talent acquisition, performance management, and organizational development across the Double Impact, Life Sciences, Real Estate, and Tech Opportunities teams. Before Bain Capital, she held HR relationship management and global talent acquisition roles at Wellington Management Company and earlier worked in HR and recruiting at J.P. Morgan. She holds an AB from Bowdoin College and an MA in organizational psychology from Columbia University Teachers' College.

Melaku Arega is a Vice President on the Life Sciences team at Bain Capital, which he joined in 2022. Before that, he attended Harvard Medical School, completing clinical training at Beth Israel Medical Center and other Harvard-affiliated hospitals, and conducted research on cancer care disparities. He holds an MD from Harvard Medical School, an MBA from Harvard Business School, and a BS in neuroscience and molecular & cellular biology from Johns Hopkins University.

Melissa Danforth is Executive Chairman of Africa Health Business, a pan-African healthcare advisory, consulting, and investment firm, and founded Avenue Healthcare, a private healthcare provider in Kenya, in 1995. She serves as President of the Africa Healthcare Federation and Chairperson of the Kenya Health Professionals Oversight Authority, and sits on advisory bodies including MSD for Mothers and the IFC Ethical Principles in Health Care Advisory Board. In 2024, she received the Elder of the Burning Spear (EBS) honor from the President of Kenya for contributions to healthcare and national development.

Molly Lawrence joined Bain Capital in 2025 as a Vice President of Human Resources, where she leads recruiting, development, and engagement efforts for the Life Sciences team. She previously served as Vice President of Talent Management and Development at Audax Private Equity and held talent roles at Bain & Company. She holds a BA from Dartmouth College.

Sharad Goyal is Senior Vice President and Head of IT for Private Markets at Bain Capital, which he joined in 2007. Before Bain Capital, he held technology consulting roles in the Global Capital Markets division of Sapient (now Publicis.Sapient). He holds an MBA in finance from Management Development Institute in India, along with a master's in computer science and a bachelor's in finance.

Shuvam Chaudhuri is an Associate on the Life Sciences team at Bain Capital, which he joined in 2023, having previously served as a Life Sciences Fellow. He completed his doctoral research at Northwestern University, studying transcriptional mechanisms of immune cell differentiation in cancer, infection, and autoimmunity, and earlier worked in antiviral drug discovery at Janssen Research and Development.

Andrew Carlino is a Senior Advisor at Bain Capital, which he joined in 2002. He previously oversaw the Credit group's investments in the airlines, aerospace & defense, and homebuilding & building products sectors. Before Bain Capital, he was a consultant at The Boston Consulting Group and an intelligence officer in the US Air Force, and he holds an MBA from the University of Chicago Booth School of Business and a BS from the United States Air Force Academy.

Ben Nye, ex-Turbonomic CEO and former Bain Capital Ventures investor, is an operator-heavy partner who founded a Sales Academy and helps founders hire, ramp sales teams and build go-to-market playbooks.

Kees Kruythoff is a business executive with 27 years at Unilever, where he served as President of North America and President of the Global Home Care division as a member of the global executive team. Following his departure from Unilever in 2019, he co-founded IMAGINE.one, a for-benefit organization focused on climate and inequality, and served as chairman and CEO of LIVEKINDLY Collective, a plant-based food company comprising multiple brands. He currently serves as Thematic Chair for Sustainable Foods at Summa Equity, invests in food technology startups through Nicoya and Bain Capital, and holds board positions including chairman of MrGreenAfrica and board member of RCL Foods.

Michael Chagnon is Vice President of Finance at Bain Capital Ventures and Bain Capital Crypto. He holds a Master of Science in Taxation and has a technical background in partnership and mutual fund tax accounting.

Sarah Hinkfuss specializes in climate fintech—B2B payments, insurance, and wealthtech—seeking decarbonizing software and financial products, leveraging SVP operating experience at Applied Predictive Technologies (acquired by Mastercard) and growth-to-early-stage investing.

Michael Cooney is a Vice President on the Life Sciences team at Bain Capital, which he joined in 2021 after serving as a Life Sciences fellow. Before Bain Capital, he was a graduate student researcher in the Department of Genetics at Harvard Medical School, focusing on genomic instability and epigenetic dysfunction in aging, and earlier worked at Genocea Biosciences on pre-clinical and clinical research into T-cell-inducing vaccines. He holds a PhD in biological and biomedical sciences from Harvard University and BS degrees in biology and biotechnology from Tufts University.